Université Paris-Est Creteil, Immunorégulation et Biothérapie, INSERM U955, Hôpital Henri Mondor, F-94010 Créteil, France.
Université Paris-Est Creteil, CNRS, Institut Chimie et Matériaux Paris Est, UMR 7182, 2 Rue Henri Dunant, F-94320 Thiais, France.
Nanotechnology. 2021 May 17;32(32). doi: 10.1088/1361-6528/abfb30.
Conventional chemotherapy used against cancer is mostly limited due to their non-targeted nature, affecting normal tissue and causing undesirable toxic effects to the affected tissue. With the aim of improving these treatments both therapeutically and in terms of their safety, numerous studies are currently being carried out using nanoparticles (NPs) as a vector combining tumor targeting and carrying therapeutic tools. In this context, it appears that nucleolin, a molecule over-expressed on the surface of tumor cells, is an interesting therapeutic target. Several ligands, antagonists of nucleolin of various origins, such as AS1411, the F3 peptide and the multivalent pseudopeptide N6L have been developed and studied as therapeutic tools against cancer. Over the last ten years or so, numerous studies have been published demonstrating that these antagonists can be used as tumor targeting agents with NPs from various origins. Focusing on nucleolin ligands, the aim of this article is to review the literature recently published or under experimentation in our research team to evaluate the efficacy and future development of these tools as anti-tumor agents.
传统的癌症化疗由于其非靶向性，会对正常组织产生影响，并对受影响的组织产生不良的毒性作用，因此大多受到限制。为了提高这些治疗方法的疗效和安全性，目前正在使用纳米粒子（NPs）作为载体，结合肿瘤靶向和携带治疗工具进行大量研究。在这方面，核仁素似乎是一种很有前途的治疗靶点，它是一种在肿瘤细胞表面过度表达的分子。已经开发并研究了多种配体，即核仁素的各种来源的拮抗剂，如 AS1411、F3 肽和多价假肽 N6L，作为抗癌治疗工具。在过去的十年左右，已经发表了许多研究，证明这些拮抗剂可以与来自不同来源的 NPs 一起用作肿瘤靶向剂。本文重点介绍核仁素配体，旨在综述我们研究团队最近发表或正在进行的研究文献，以评估这些工具作为抗肿瘤药物的疗效和未来发展。
